Literature DB >> 17495487

Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.

Pietro Pepe1, Paolo Panella, Francesco Savoca, Antonio Cacciola, Letterio D'Arrigo, Giuseppe Dibenedetto, Michele Pennisi, Francesco Aragona.   

Abstract

AIM: To report prevalence and clinical relevance of T1c prostate cancers (PCa) in a selected population of men with serum prostate-specific antigen (PSA) levels < or =4 ng/ml enrolled in a multicenter case-finding protocol. PATIENTS AND METHODS: A number of 16,298 men, aged 40-75 years, from the urology units they had been referred to, in most cases (81.6%) for lower urinary tract symptoms, were evaluated. Eighty percent of them had PSA < or =4 ng/ml and about 40% PSA < or =2.5 ng/ml. Patients with PSA < or =2.5 ng/ml and PSA between 2.6 and 4 ng/ml and with percent free PSA < or =15 and < or =20%, respectively, were eligible for biopsy; 28 patients refused it, and 11 patients were excluded from the study because of an abnormal digital rectal examination. Among 403 biopsied men, 82 had PSA < or =2.5 ng/ml (group A) and 321 PSA between 2.6 and 4 ng/ml (group B).
RESULTS: A PCa was found in 109 cases (27.0%): 21 in group A and 88 in group B. 48 (44%) of the 109 patients with a PCa underwent radical prostatectomy: all cancers had a volume >0.5 cm(3), and 41% had a final Gleason sum > or =7; the PCa was organ confined in 34 patients (70.8%) and locally advanced in 14 patients (29.1%), and in 12 patients (25%) positive surgical margins were found.
CONCLUSIONS: Using percent free PSA thresholds of 15 and 20%, 25.6% of the men with PSA < or =2.5 ng/ml and 27.4% of the men with PSA between 2.6 and 4 ng/ml were found to have a PCa, respectively. Most of these cancers, when submitted to radical prostatectomy, were found to be clinically significant. As these cancers are mostly organ confined, these patients are ideal candidates for curative nerve-sparing surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495487     DOI: 10.1159/000100833

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  3 in total

1.  Assays for prostate cancer : changing the screening paradigm?

Authors:  Jens Hansen; Michael Rink; Markus Graefen; Shahrokh Shariat; Felix K-H Chun
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

2.  Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients.

Authors:  Samuel W D Merriel; Lucy Pocock; Emma Gilbert; Sam Creavin; Fiona M Walter; Anne Spencer; Willie Hamilton
Journal:  BMC Med       Date:  2022-02-07       Impact factor: 8.775

3.  Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.

Authors:  Ryan Stuchbery; Geoff Macintyre; Marek Cmero; Laurence M Harewood; Justin S Peters; Anthony J Costello; Christopher M Hovens; Niall M Corcoran
Journal:  Oncotarget       Date:  2016-05-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.